We are monitoring the impact of COVID-19 on Europe Liver Disease Treatment Market Get in touch with us for detailed analysis Know More
Share on

Europe Liver Disease Treatment Market Research Report – Segmented By Treatment Modality, Disease Type and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) - Industry Size, Share, Trends and Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1652
Pages: 145

Europe Liver Disease Treatment Market Size (2022 to 2027)

The size of the Liver Disease Treatment Market in the European region is expected to reach USD 4.01 billion by 2027 from USD 2.32 billion in 2022, growing at a CAGR of 11.56% during the forecast period.

The percentage of the aged population diagnosing with liver-related diseases is significantly increasing in Europe and is primarily driving the growth of the European liver disease treatment market. Europe is among one of the leading markets for Liver Disease Treatment Drugs. As per a report, liver cirrhosis causes 170,000 deaths in Europe annually. Within Europe, Germany, France, and the United Kingdom account for the largest liver disease treatment market share.

Various technological advancements in the imaging techniques, Y-O-Y increase in the patients diagnosing with the liver diseases further contribute to the growth of the market. The increasing number of mergers and acquisitions that are happening between the companies is predicted to shape the face of the market better during the forecast period. The license expiration of a few drugs and robust pipeline drugs for the treatment of liver diseases is adding fuel to the market.

Strict regulations of the FDA, MHRA in approving the new drugs, and high costs required for the development of new drugs, and the high costs associated with the treatment for liver diseases are expected to hamper the market growth to a specific limit.

This research report on the Europe Liver Disease Treatment Market has been segmented and sub-segmented into the following categories:

By Treatment Modality:

  • Antiviral
  • Vaccines
  • Chemotherapy
  • Immunosuppressive Agents
  • Corticosteroids

By Disease Type:

  • Hepatitis
  • Non-Alcoholic Fatty Liver Disease
  • Alcohol-Induced
  • Liver Cancer

By Country:

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Rest of Europe

Regional Analysis:

Geographically, the European liver disease treatment market stands second, following North America in leading the global liver disease treatment market. It is due to viral hepatitis, genetic disorders, unhealthy diet, and excessive intake of alcohol.

Germany, UK, and France account for significant shares of the liver disease treatment market in the region. The growing number of liver disease cases because of the vast drinking population in Europe and increasing obesity and growing new clinical needs in liver diseases are likely to accelerate market growth. The Germany market is rising due to factors like excess intake of over-the-counter high dosage drugs, reimbursement policies for liver diseases in the healthcare sector, government, and other private organizations bring out the awareness by organizing programs regarding liver disease treatment which propels the market during the analysis period. Alcohol consumption is considered to cause 20%-50%of cirrhosis of the liver, and around 13% of the population across the globe, i.e., more than 600 million adults, are obese according to World Health Organization. Moreover, Cirrhosis can cause 170,000 deaths in Europe every year.

Companies playing a vital role in the European Liver Disease Treatment Market profiled in the report are Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland), Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer Schering AG (Germany) and AstraZeneca (United Kingdom).

1.Introduction                                                  

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                          

                1.4 General Study Assumptions                                

  1. Research Methodology

                2.1 Introduction                                               

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

  1. Overview

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 Epidemology                                              

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                              

  1. Market Segmentation

                5.1 Treatment Modality                                               

                                5.1.1 Introduction                           

                                5.1.2 Antiviral                    

                                5.1.3 Vaccines                   

                                5.1.4 Chemotherapy                      

                                5.1.5 Immunosuppressive Agents                           

                                5.1.6 Corticosteroids                      

                                5.1.7 Others                      

                                5.1.8  Y-o-Y Growth Analysis, By Product                              

                                5.1.9  Market Attractiveness Analysis, By Product                            

                                5.1.10 Market Share Analysis, By Product                             

                5.2 Disease Type                                             

                                5.2.1 Introduction                           

                                5.2.2 Hepatitis                  

                                5.2.3 Non-Alcoholic Fatty Liver Disease                 

                                5.2.4 Alcohol Induced                    

                                5.2.5 Liver Cancer                            

                                5.2.6 Others                      

                                5.2.7  Y-o-Y Growth Analysis, By Type                    

                                5.2.8  Market Attractiveness Analysis, By Type                  

                                5.2.9  Market Share Analysis, By Type                    

  1. Geographical Analysis

                6.1 Introduction                                               

                                6.1.1 Regional Trends                    

                                6.1.2 Impact Analysis                     

                                6.1.3 Y-o-Y Growth Analysis                        

                                                6.1.3.1 By Geographical Area     

                                                6.1.3.2 By Product           

                                                6.1.3.3 By Type 

                                                6.1.3.4 By Application    

                                                6.1.3.5 By Indication       

                                6.1.4  Market Attractiveness Analysis                     

                                                6.1.4.1 By Geographical Area     

                                                6.1.4.2 By Product           

                                                6.1.4.3 By Type 

                                                6.1.4.4 By Application    

                                                6.1.4.5 By Indication       

                                6.1.5  Market Share Analysis                      

                                                6.1.5.1 By Geographical Area     

                                                6.1.5.2 By Product           

                                                6.1.5.3 By Type 

                                                6.1.5.4 By Application    

                                                6.1.5.5 By Indication       

                6.2 U.K                                 

                6.3 Spain                                             

                6.4 Germany                                     

                6.5 Italy                                               

                6.6 France                                          

7.Strategic Analysis                                                        

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

8.Market Leaders' Analysis                                                         

                8.1 Gilead Science Inc                                    

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Financial analysis                  

                                8.1.4 Recent Developments                       

                                8.1.5 SWOT analysis                       

                                8.1.6 Analyst View                          

                8.2 Pfizer Inc.                                    

                8.3 Merck & Co.                                               

                8.4 Johnson & Johnson                                 

                8.5 Novartis                                       

                8.6 Roche                                           

                8.7 Sanofi-Aventis                                          

                8.8 Abbott Laboratories                                               

                8.9 Bayer Schering AG                                   

                8.10 AstraZeneca                                            

9.Competitive Landscape                                                            

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

10.Market Outlook and Investment Opportunities                                                          

Appendix                                                           

  1. a) List of Tables
  2. b) List of Figures
  1. Europe Liver Disease Treatment Market, By Treatment Modality , From 2022 - 2027 (USD Billion)
  2. Europe Antiviral Market, By Region, From 2022 - 2027 (USD Billion)
  3. Europe Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  4. Europe Chemotherapy Market, By Region, From 2022 - 2027 (USD Billion)
  5. Europe Immunosuppressive Agents Market, By Region, From 2022 - 2027 (USD Billion)
  6. Europe Corticosteroids Market, By Region, From 2022 - 2027 (USD Billion)
  7. Europe Others Market, By Region, From 2022 - 2027 (USD Billion)
  8. Europe Liver Disease Treatment Market, By Disease Type, From 2022 - 2027 (USD Billion)
  9. Europe Hepatitis Market, By Region, From 2022 - 2027 (USD Billion)
  10. Europe Non-Alcoholic Fatty Liver Disease Market, By Region, From 2022 - 2027 (USD Billion)
  11. Europe Alcohol Induced Market, By Region, From 2022 - 2027 (USD Billion)
  12. Europe Liver Cancer Market, By Region, From 2022 - 2027 (USD Billion)
  13. Europe Others Market, By Region, From 2022 - 2027 (USD Billion)
  14. U.K. Liver Disease Treatment Market, By Treatment Modality , From 2022 - 2027 (USD Billion)
  15. U.K. Liver Disease Treatment Market, By Disease Type, From 2022 - 2027 (USD Billion)
  16. Germany Liver Disease Treatment Market, By Treatment Modality , From 2022 - 2027 (USD Billion)
  17. Germany Liver Disease Treatment Market, By Disease Type, From 2022 - 2027 (USD Billion)
  18. France Liver Disease Treatment Market, By Treatment Modality , From 2022 - 2027 (USD Billion)
  19. France Liver Disease Treatment Market, By Disease Type, From 2022 - 2027 (USD Billion)
  20. Italy Liver Disease Treatment Market, By Treatment Modality , From 2022 - 2027 (USD Billion)
  21. Italy Liver Disease Treatment Market, By Disease Type, From 2022 - 2027 (USD Billion)
  22. Spain Liver Disease Treatment Market, By Treatment Modality , From 2022 - 2027 (USD Billion)
  23. Spain Liver Disease Treatment Market, By Disease Type, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample